Correlation between Chemokine Receptor CXCR4 Expression and Prognostic Factors in Patients with Prostate Cancer

다국어 초록 (Multilingual Abstract)

Purpose: We evaluated the correlation between the expression of CXCR4 and prognostic factors in patients with prostate cancer.
Materials and Methods: A total of 57 patients who had undergone surgery for prostate cancer were enrolled. Specimens were obtained before any treatment and were stained with antihuman CXCR4 antibody. The intensity of staining was graded as low or high. The age, pretreatment prostate-specific antigen (PSA) level, Gleason score, T stage, biochemical recurrence, local recurrence, and distant metastasis were compared according to the expression of CXCR4 in patients with prostate cancer.
Results: Local recurrence was higher in the group with high expression, in 11 of 36 cases (30.6%), than in the group with low expressiron, in 1 of 21 cases (4.8%), with statistical significance (p=0.040). Distant metastasis was also associated with expression, occurring in 10 of 36 cases (27.8%) in the group with high expression and in 1 of 21 cases (4.8%) in the group with low expression (p=0.041). In the logistic regression test, CXCR4 expression was the only factor in determining local recurrence (p=0.016) and distant metastasis (0.022). Furthermore, the group with high CXCR4 expression showed significantly longer cancer-specific survival than did the low expression group (p=0.041). CXCR4 showed no association with age (p=0.881), pretreatment PSA level (p=0.584), Gleason score (p=0.640), T stage (p=0.967), or biochemical recurrence (p=0.081).
Conclusions: The high expression of CXCR4 was associated with local recurrence and distant metastasis. CXCR4 expression was shown to be a useful prognostic factor for patients with prostate cancer.

참고문헌 (Reference)

1 Mochizuki H, "of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis" 30 : 656-663, 2004

2 Taichman RS, "Use of the stromal cell-derived Factor-1/CXCR4 pathway in prostate cancer metastasis to bone" 62 : 1832-1837, 2002

3 Andrew DP, "Transendothelial migration and trafficking of leukocytes in LFA-1-deficient mice" 28 : 1959-1969, 1998

4 Payne AS, "The role of chemokines in melanoma tumor growth and metastasis" 118 : 915-922, 2002

5 Tamamura H, "T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer" 28 : 79-83, 2003

6 Kijima T, "Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells" 62 : 6304-6311, 2002

7 Engl T, "Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix" 78 : 1784-1793, 2006

8 De Clercq E, "Potential clinical applications of the CXCR4 antagonist Bicyclam AMD3100" 5 : 805-824, 2005

9 Koishi K, "Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer" 12 : 7585-7590, 2006

10 Scotton CJ, "Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer" 62 : 5930-5938, 2002

11 Matthew J. Roberts, "Metabolomics: A Novel Approach to Early and Noninvasive Prostate Cancer Detection" 대한비뇨기과학회 52 (52): 79-89, 2011

12 Müller A, "Involvement of chemokine receptors in breast cancer metastasis" 410 : 50-56, 2001

13 Wang J, "Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype" 64 : 1861-1866, 2004

14 Jiang YP, "Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression" 103 : 226-233, 2006

15 Scala S, "Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma" 11 : 1835-1841, 2005

16 Murakami T, "Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells" 62 : 7328-7334, 2002

17 Zlotnik A, "Chemokines: a new classification system and their role in immunity" 12 : 121-127, 2000

18 Constantin G, "Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow" 13 : 759-769, 2000

19 Akashi T, "Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer" 99 : 539-542, 2008

20 Spano JP, "Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome" 15 : 613-617, 2004

21 Smith MC, "CXCR4 regulates growth of both primary and metastatic breast cancer" 64 : 8604-8612, 2004

22 König JE, "Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer" 58 : 121-129, 2004

23 Foster SJ, "Acute inflammatory effects of a monocyte-derived neutrophil-activating peptide in rabbit skin" 67 : 181-183, 1989

24 Mitchison TJ, "Actin-based cell motility and cell locomotion" 84 : 371-379, 1996

25 Rubin JB, "A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors" 100 : 13513-13518, 2003

26 Takenaga M, "A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma" 320 : 226-232, 2004